The demonstration of reduced heart failure, death and other cardiovascular benefits with major classes of diabetes drugs means cardiovascular products like Novartis AG's congestive heart failure therapy Entresto must deal with imminent – and unexpected – competition from marketed metabolic drugs broadening their reach.
See Related Story
For more on Entresto's performance over time: (Also see "Novartis's Entresto Voyage: Hindsight Is 20/20" - Scrip, 15 May, 2017.)
Entresto (valsartan/sacubitril) has finally started to make its mark on the CHF market, but there are other products moving up...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?